Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin–paclitaxel

European Journal of Health Economics

Volumn 17, Issue 7, 2016, Pages 855-863

  Arrieta, Oscar ^a   Anaya, Pablo ^b   Morales Oyarvide, Vicente ^a   Ramírez Tirado, Laura Alejandra ^a   Polanco, Ana C ^c  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b IQVIA   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Carcinoma; Cost benefit analysis; Developing countries; Health policy; Mutation; Non small cell lung

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PACLITAXEL; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ACNE; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CONSTIPATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; FEBRILE NEUTROPENIA; HUMAN; INCIDENCE; LEUKOPENIA; MEXICAN; MONTE CARLO METHOD; MUTATION RATE; MYALGIA; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; PARONYCHIA; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SENSITIVITY ANALYSIS; STOMATITIS; SURVIVAL RATE; UNITED STATES; VOMITING; CARCINOMA, NON-SMALL-CELL LUNG; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; ECONOMICS; FEMALE; GENETICS; LUNG NEOPLASMS; MALE; MEXICO; MUTATION; PROTO ONCOGENE; QUALITY ADJUSTED LIFE YEAR; SOUTH AND CENTRAL AMERICA; STATISTICAL MODEL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; GENES, ERBB-1; HUMANS; LATIN AMERICA; LUNG NEOPLASMS; MALE; MEXICO; MODELS, ECONOMETRIC; MUTATION; PACLITAXEL; PROTEIN KINASE INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; QUINAZOLINES;

EID: 84940703187     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-015-0726-5     Document Type: Article

References (47)

1. Arrieta, O., Guzmán-de Alba, E., Alba-López, L.F., Acosta-Espinoza, A., Alatorre-Alexander, J., Alexander-Meza, J.F., Allende-Pérez, S.R., Alvarado-Aguilar, S., Araujo-Navarrete, M.E., Argote-Greene, L.M., Aquino-Mendoza, C.A., Astorga-Ramos, A.M., Astudillo-de la Vega, A., Avilés-Salas, A., Barajas-Figueroa, L.J., Barroso-Quiroga, N., Blake-Cerda, M., Cabrera-Galeana, P.A., Calderillo-Ruíz, G., Campos-Parra, A.D., et al.: Consenso nacional de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas. Rev. Invest. Cli. 65(Suppl 1), S5–S84 (2013)
2. Geografía, I.N.d.E.y. http://www.inegi.org.mx/ (2014). Accessed 5 May 2014
3. Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D.: Global cancer statistics. CA Cancer J. Clin. 61(2), 69–90 (2011). doi:10.3322/caac.20107
4. Society, A.C.: Cancer facts & figures 2013. In: Society, A.C. (ed.). Atlanta (2013)
5. Arrieta, O., Martinez-Barrera, L., Trevino, S., Guzman, E., Castillo-Gonzalez, P., Rios-Trejo, M.A., Flores-Estrada, D., Tellez, E., Gonzalez, C., de la Cruz Vargas, J., Gonzalez-De la Rosa, C.H., Hernandez-Pedro, N., Morales-Barrera, R., De la Garza, J.: Wood-smoke exposure as a response and survival predictor in erlotinib-treated non-small cell lung cancer patients: an open label phase II study. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 3(8), 887–893 (2008). doi:10.1097/JTO.0b013e31818026f6
6. Delbaldo, C., Michiels, S., Syz, N., Soria, J.C., Le Chevalier, T., Pignon, J.P.: Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 292(4), 470–484 (2004). doi:10.1001/jama.292.4.470
7. Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., Eek, R., Horai, T., Noda, K., Takata, I., Smit, E., Averbuch, S., Macleod, A., Feyereislova, A., Dong, R.P., Baselga, J.: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) [corrected]. J.Clin. Oncol. Off. J Am. Soc. Clin. Oncol. 21(12), 2237–2246 (2003). doi:10.1200/JCO.2003.10.038
8. Spiro, S.G., Silvestri, G.A.: The treatment of advanced non-small cell lung cancer. Curr. Opin. Pulm. Med. 11(4), 287–291 (2005)
9. Group NMAC: Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J.Clin. Oncol. Off. J Am. Soc. Clin. Oncol. 26(28), 4617–4625 (2008). doi:10.1200/JCO.2008.17.7162
10. Kris, M.G., Natale, R.B., Herbst, R.S., Lynch Jr, T.J., Prager, D., Belani, C.P., Schiller, J.H., Kelly, K., Spiridonidis, H., Sandler, A., Albain, K.S., Cella, D., Wolf, M.K., Averbuch, S.D., Ochs, J.J., Kay, A.C.: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290(16), 2149–2158 (2003). doi:10.1001/jama.290.16.2149
11. Shiroiwa, T., M.Y., Tsutani, K.: Cost-effectiveness analysis of EGFR testing and gefitinib for non small-cell lung cancer (NSCLC) in Japan. Paper presented at the 17th annual international meeting of the International Society for Pharmaeconomics and Outcomes Research (ISPOR), Washington, USA, 2–6 June 2012
12. Shepherd, F.A., Pereira, J.R., Ciuleanu, T., Tan, E.H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., van Kooten, M., Dediu, M., Findlay, B., Tu, D., Johnston, D., Bezjak, A., Clark, G., Santabarbara, P., Seymour, L., National Cancer Institute of Canada Clinical Trials G: Erlotinib in previously treated non-small-cell lung cancer. New Engl. J. Med. 353(2), 123–132 (2005). doi:10.1056/NEJMoa050753
13. Thatcher, N., Chang, A., Parikh, P., Pereira, J.R., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E.H., Pemberton, K., Archer, V., Carroll, K.: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496), 1527–1537 (2005). doi:10.1016/S0140-6736(05)67625-8
14. Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., Louis, D.N., Christiani, D.C., Settleman, J., Haber, D.A.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl. J. Med. 350(21), 2129–2139 (2004). doi:10.1056/NEJMoa040938
15. Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M.J., Sellers, W.R., Johnson, B.E., Meyerson, M.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676), 1497–1500 (2004). doi:10.1126/science.1099314
16. Mok, T.S., Wu, Y.L., Thongprasert, S., Yang, C.H., Chu, D.T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J.J., Chewaskulyong, B., Jiang, H., Duffield, E.L., Watkins, C.L., Armour, A.A., Fukuoka, M.: Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. New Engl. J. Med. 361(10), 947–957 (2009). doi:10.1056/NEJMoa0810699
17. Park, K., Goto, K.: A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr. Med. Res. Opin. 22(3), 561–573 (2006). doi:10.1185/030079906X89847
18. Han, J.Y., Park, K., Kim, S.W., Lee, D.H., Kim, H.Y., Kim, H.T., Ahn, M.J., Yun, T., Ahn, J.S., Suh, C., Lee, J.S., Yoon, S.J., Han, J.H., Lee, J.W., Jo, S.J., Lee, J.S.: First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J.Clin. Oncol. Off. J Am. Soc. Clin. Oncol. 30(10), 1122–1128 (2012). doi:10.1200/JCO.2011.36.8456
19. Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., Fujita, Y., Okinaga, S., Hirano, H., Yoshimori, K., Harada, T., Ogura, T., Ando, M., Miyazawa, H., Tanaka, T., Saijo, Y., Hagiwara, K., Morita, S., Nukiwa, T., North-East Japan Study G: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New Engl. J. Med. 362(25), 2380–2388 (2010). doi:10.1056/NEJMoa0909530
20. Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., Asami, K., Katakami, N., Takada, M., Yoshioka, H., Shibata, K., Kudoh, S., Shimizu, E., Saito, H., Toyooka, S., Nakagawa, K., Fukuoka, M., West Japan Oncology G: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11(2), 121–128 (2010). doi:10.1016/S1470-2045(09)70364-X
21. Zhou, C., Wu, Y.L., Chen, G., Feng, J., Liu, X.Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., Lu, S., Zhang, L., Hu, C., Hu, C., Luo, Y., Chen, L., Ye, M., Huang, J., Zhi, X., Zhang, Y., Xiu, Q., Ma, J., Zhang, L., You, C.: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12(8), 735–742 (2011). doi:10.1016/S1470-2045(11)70184-X
22. Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J.M., Porta, R., Cobo, M., Garrido, P., Longo, F., Moran, T., Insa, A., De Marinis, F., Corre, R., Bover, I., Illiano, A., Dansin, E., de Castro, J., Milella, M., Reguart, N., Altavilla, G., Jimenez, U., Provencio, M., Moreno, M.A., Terrasa, J., Munoz-Langa, J., Valdivia, J., Isla, D., Domine, M., Molinier, O., Mazieres, J., Baize, N., Garcia-Campelo, R., Robinet, G., Rodriguez-Abreu, D., Lopez-Vivanco, G., Gebbia, V., Ferrera-Delgado, L., Bombaron, P., Bernabe, R., Bearz, A., Artal, A., Cortesi, E., Rolfo, C., Sanchez-Ronco, M., Drozdowskyj, A., Queralt, C., de Aguirre, I., Ramirez, J.L., Sanchez, J.J., Molina, M.A., Taron, M., Paz-Ares, L., Spanish Lung Cancer Group in collaboration with Groupe Francais de, P.-C, Associazione Italiana Oncologia T: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13(3), 239–246 (2012). doi:10.1016/S1470-2045(11)70393-X
23. Sequist, L.V., Yang, J.C., Yamamoto, N., O’Byrne, K., Hirsh, V., Mok, T., Geater, S.L., Orlov, S., Tsai, C.M., Boyer, M., Su, W.C., Bennouna, J., Kato, T., Gorbunova, V., Lee, K.H., Shah, R., Massey, D., Zazulina, V., Shahidi, M., Schuler, M.: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J.Clin. Oncol. Off. J Am. Soc. Clin. Oncol. 31(27), 3327–3334 (2013). doi:10.1200/JCO.2012.44.2806
24. Wu, Y.L., Zhou, C., Hu, C.P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J.H., Lee, K.Y., Xu, C.R., Massey, D., Kim, M., Shi, Y., Geater, S.L.: Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 15(2), 213–222 (2014). doi:10.1016/S1470-2045(13)70604-1
25. Arrieta, O., Cardona, A.F., Bramuglia, G.F., Gallo, A., Campos-Parra, A.D., Serrano, S., Castro, M., Aviles, A., Amorin, E., Kirchuk, R., Cuello, M., Borbolla, J., Riemersma, O., Becerra, H., Rosell, R., ClicaP: Genotyping non-small cell lung cancer (NSCLC) in Latin America. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 6(11), 1955–1959 (2011). doi:10.1097/JTO.0b013e31822f655f
26. Arrieta, O., Cardona, A.F., Martin, C., Mas-Lopez, L., Corrales-Rodriguez, L., Bramuglia, G., Castillo-Fernandez, O., Meyerson, M., Amieva-Rivera, E., Campos-Parra, A.D., Carranza, H., de Gomez la Torre, J.C., Powazniak, Y., Aldaco-Sarvide, F., Vargas, C., Trigo, M., Magallanes-Maciel, M., Otero, J., Sanchez-Reyes, R., Cuello, M.: Updated frequency of EGFR and KRAS mutations in non-small-cell lung cancer in Latin America: the Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). thorac. oncol. off. publ. Int. Assoc. Study Lung Cancer 10(5), 838–843 (2015). doi:10.1097/JTO.0000000000000481
27. Arrieta, O., Nunez-Valencia, C., Reynoso-Erazo, L., Alvarado, S., Flores-Estrada, D., Angulo, L.P., Onate-Ocana, L.F.: Health-related quality of life in patients with lung cancer: validation of the Mexican-Spanish version and association with prognosis of the EORTC QLQ-LC13 questionnaire. Lung Cancer 77(1), 205–211 (2012). doi:10.1016/j.lungcan.2012.02.005
28. Campos-Parra, A.D., Zuloaga, C., Manriquez, M.E., Aviles, A., Borbolla-Escoboza, J., Cardona, A., Meneses, A., Arrieta, O.: KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making. Am. J. Clin. Oncol. 38(1), 33–40 (2015). doi:10.1097/COC.0b013e318287bb23
29. Arrieta, O., Cardona, A.F., Corrales, L., Campos-Parra, A.D., Sanchez-Reyes, R., Amieva-Rivera, E., Rodriguez, J., Vargas, C., Carranza, H., Otero, J., Karachaliou, N., Astudillo, H., Rosell, R., ClicaP: The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. Lung Cancer 87(2), 169–175 (2015). doi:10.1016/j.lungcan.2014.12.009
30. Heon, S., Yeap, B.Y., Lindeman, N.I., Joshi, V.A., Butaney, M., Britt, G.J., Costa, D.B., Rabin, M.S., Jackman, D.M., Johnson, B.E.: The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 18(16), 4406–4414 (2012). doi:10.1158/1078-0432.CCR-12-0357
31. Arrieta, O., Campos-Parra, A.D., Zuloaga, C., Aviles, A., Sanchez-Reyes, R., Manriquez, M.E., Covian-Molina, E., Martinez-Barrera, L., Meneses, A., Cardona, A., Borbolla-Escoboza, J.R.: Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 7(8), 1228–1234 (2012). doi:10.1097/JTO.0b013e3182582a93
32. Chen, W., E.P., Levin, L., et al.: Cost-effectiveness of epidermal growth factor receptor gene mutation testing in the selection of first-line therapy for patients with advanced non-small cell lung cancer in Ontario. Paper presented at the 16th annual international meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Baltimore, USA, 21–25 May
33. Jacob, J., H.M., Brattstrbm, D.: Cost-effectiveness of gefitinib versus doublet chemotherapy in first-line treatment of non-small cell lung cancer (NSCLC) in Sweden. Paper presented at 13th annual European congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Prague, Czech Republic., 6–9 Nov
34. de Lima Lopes Jr, G., Segel, J.E., Tan, D.S., Do, Y.K., Mok, T., Finkelstein, E.A.: Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer 118(4), 1032–1039 (2012). doi:10.1002/cncr.26372
35. Arrieta, O., Quintana-Carrillo, R.H., Ahumada-Curiel, G., Corona-Cruz, J.F., Correa-Acevedo, E., Zinser-Sierra, J., de la Mata-Moya, D., Mohar-Betancourt, A., Morales-Oyarvide, V., Reynales-Shigematsu, L.M.: Medical care costs incurred by patients with smoking-related non-small cell lung cancer treated at the national cancer institute of Mexico. Tob. Induc. Dis. 12(1), 25 (2014). doi:10.1186/s12971-014-0025-4
36. Kohler, J., Schuler, M.: Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review. Onkologie 36(9), 510–518 (2013). doi:10.1159/000354627
37. Kim, E.S., Hirsh, V., Mok, T., Socinski, M.A., Gervais, R., Wu, Y.L., Li, L.Y., Watkins, C.L., Sellers, M.V., Lowe, E.S., Sun, Y., Liao, M.L., Osterlind, K., Reck, M., Armour, A.A., Shepherd, F.A., Lippman, S.M., Douillard, J.Y.: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372(9652), 1809–1818 (2008). doi:10.1016/S0140-6736(08)61758-4
38. Westwood, M., Joore, M., Whiting, P., van Asselt, T., Ramaekers, B., Armstrong, N., Misso, K., Severens, J., Kleijnen, J.: Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis. Health Technol. Assess. 18(32), 1–166 (2014). doi:10.3310/hta18320
39. Health Quality O: Epidermal growth factor receptor mutation (EGFR) testing for prediction of response to EGFR-targeting tyrosine kinase inhibitor (TKI) drugs in patients with advanced non-small-cell lung cancer: an evidence-based analysis. Ont. Health Technol. Assess. Ser. 10(24), 1–48 (2010)
40. Handorf, E.A., McElligott, S., Vachani, A., Langer, C.J., Bristol Demeter, M., Armstrong, K., Asch, D.A.: Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung. J. Oncol. Pract. Am. Soc. Clin. Oncol. 8(5), 267–274 (2012). doi:10.1200/JOP.2011.000502
41. Romanus, D., Cardarella, S., Cutler, D., Landrum, M.B., Lindeman, N.I., Gazelle, G.S.: Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 10(4), 586–594 (2015). doi:10.1097/JTO.0000000000000474
42. Wang, S., Peng, L., Li, J., Zeng, X., Ouyang, L., Tan, C., Lu, Q.: A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer. PLoS One 8(3), e55917 (2013). doi:10.1371/journal.pone.0055917
43. Carlson, J.J., Garrison, L.P., Ramsey, S.D., Veenstra, D.L.: Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. J. Cancer Res. Clin. Oncol. 135(11), 1483–1493 (2009). doi:10.1007/s00432-009-0595-3
44. Graham, D.M., Leighl, N.B.: Economic impact of tissue testing and treatments of metastatic NSCLC in the era of personalized medicine. Front. oncol. 4, 258 (2014). doi:10.3389/fonc.2014.00258
45. Hayes, D.N., Kim, W.Y.: The next steps in next-gen sequencing of cancer genomes. J. Clin. Investig. 125(2), 462–468 (2015). doi:10.1172/JCI68339
46. Dawe, D.E., Ellis, P.M.: Challenges in implementing personalized medicine for lung cancer within a national healthcare system. J. Personal. Med. 2(3), 77–92 (2012). doi:10.3390/jpm2030077
47. Carlos-Rivera, F., J, R.-G., Aguirre-Granados, A.: Cost of adverse events of bevacizumab plus interferon-alfa2a compared with sunitinib for first-line treatment of metastatic renal cell carcinoma. Gaceta Mexicana de Oncol. 9(6), 255–265 (2010)